Most cancer therapeutics ignore a fundamental fact: tumor cells are electrically active. Ben Woodington and Elise Jenkins, co-founders of Coherence Neuro, lay out the case that cancer is, in part, a bioelectric disease—one where cells hijack developmental signaling pathways to form electrically coupled networks that drive proliferation, invasion, and resistance. This is not speculative biology; they present evidence that cancer cells fire action potentials and express voltage-gated ion channels in patterns that recapitulate early neurogenesis.
The conversation centers on the SOMA device, a soft, conformable implant designed for intraoperative use. Unlike traditional neuromodulation systems that stimulate blindly, SOMA performs closed-loop sensing and stimulation: it reads impedance spectra and neurotransmitter levels to identify tumor tissue, then delivers patterned electrical stimulation to disrupt the pathological signaling. The immediate readout closes the loop—surgeons get real-time confirmation of tissue state without waiting for histology.
Key mechanistic insight: gap junctions electrically couple cancer cells into a syncytium, allowing them to share voltage signals that coordinate behavior. SOMA targets these junctions, effectively decoupling the network. The clinical focus is on the surgical margin and micrometastases—the residual disease that drives recurrence after otherwise successful resection. By framing the device as a surgical adjunct rather than a chronic implant, the team navigates a faster regulatory pathway while still building a platform technology applicable across neurology and psychiatry.
The density is high: you will learn how impedance spectroscopy distinguishes tumor from healthy tissue, why neurotransmitter sensing matters for real-time feedback, and how a startup structures its clinical strategy to reach first-in-human trials without unnecessary delay. No vague promises—just mechanism, device architecture, and clinical reasoning from two people deep in the build.
Key Insights
- Cancer cells hijack developmental bioelectric programs, forming electrical networks that functionally resemble nascent neural tissue—this is not metaphorical; they fire action potentials and wire into gap-junction syncytia.
- The SOMA device is a conformable, sub-millimeter precision implant that delivers stimulation and performs immediate biomarker readout (impedance, neurotransmitter concentration) in a single surgical workflow, eliminating the guesswork of open-loop neuromodulation.
- Impedance spectroscopy alone provides a real-time signature of tissue state—distinguishing tumor from healthy margin without waiting for pathology—because cancerous tissue exhibits distinct extracellular conductivity.
- The clinical target is not primary tumors but micrometastases and the surgical margin: the device aims to detect and electrically silence residual cells that current imaging and resection miss, directly addressing recurrence.
- Regulatory strategy treats the device as a surgical adjunct, not a chronic implant, which dramatically compresses the path to first-in-human use by leveraging existing neurosurgical frameworks rather than creating a new category.
- Coherence Neuro is building a platform, not a single-indication tool—the same closed-loop read/write architecture applies to epilepsy, Parkinson's, and psychiatric disorders, with cancer as the initial high-urgency beachhead.
Who should listen: Neurotech founders and clinical engineers designing closed-loop bioelectronic systems, or investors mapping the convergence of neuromodulation and oncology.
Why This Matters
This episode operationalizes a thesis we track closely: bioelectric medicine is moving from correlation to causal intervention. Coherence Neuro is collapsing the diagnostic and therapeutic timelines into a single intraoperative event, which changes the unit economics and regulatory calculus for neurotech startups. For builders and investors, the key signal is the shift from 'stimulate and hope' to 'read, interpret, then write'—a control-loop paradigm that demands new competencies in real-time signal processing and biomarker validation.
